Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alexander Reichard

Adult Reconstructive Orthopaedic Surgery Spokane, WA Medical Doctor

NPI 1174781421 CMS profile 143975

601 W 5Th Ave Ste 400, Spokane, WA 99204

Open in the dashboard

General payments

$49,266

72 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexander Reichard of Spokane, WA is reported in the CMS Open Payments database as having received $49,266 across 72 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Adult Reconstructive Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $858 10
2024 General $8,047 11
2023 General $9,480 17
2022 General $88 1
2021 General $1,681 14
2020 General $1,800 1
2019 General $27,311 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexander Reichard
  • Adult Reconstructive Orthopaedic Surgery median
  • Middle half of Adult Reconstructive Orthopaedic Surgery
  • National median

In program year 2025, general payments to Alexander Reichard were reported at $858. Among 1,079 Adult Reconstructive Orthopaedic Surgery profiles paid that year, the median was $1,406 and the middle half received between $318 and $8,709.

Show as a table
Year Alexander Reichard Adult Reconstructive Orthopaedic Surgery median Middle half National median
2019 $27,311 $1,416 $292–$9,336 $163
2020 $1,800 $647 $141–$6,474 $114
2021 $1,681 $1,073 $211–$6,497 $132
2022 $88 $1,217 $236–$6,299 $149
2023 $9,480 $1,082 $246–$6,818 $160
2024 $8,047 $1,575 $323–$8,944 $164
2025 $858 $1,406 $318–$8,709 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $44,914 38 payments
  2. DePuy Synthes Sales Inc. $4,125 30 payments
  3. Davol Inc. $114 2 payments
  4. Heron Therapeutics, Inc. $89 1 payment
  5. Ethicon US, LLC $23 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $40,950 11 payments
  2. Travel and Lodging $5,629 20 payments
  3. Food and Beverage $2,687 41 payments
Products named General payments · program years 2019–2025
  1. ATTUNE Ortho-Knee $29,111 19 payments
  2. ATTUNE Ortho-Knee $15,127 12 payments
  3. Velys Ortho-Knee $1,756 11 payments
  4. Velys Ortho-Hip $273 3 payments
  5. ACTIS $188 3 payments
  6. Velys Spine $105 3 payments
  7. ZYNRELEF $89 1 payment
  8. ARISTA AH FlexiTip $89 1 payment
  9. STRATAFIX $23 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

1,449

Median for Orthopedic Surgery: 203

Drug cost

$21,902

Median for Orthopedic Surgery: $1,433

Branded share of claims

7.6%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 29 $14,164
Celecoxib Generic 91 $2,167
Oxycodone Hcl Generic 276 $2,002
Amoxicillin Generic 428 $954
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 81 $758
Cephalexin Generic 204 $541
Ondansetron Hcl Generic 111 $375
Hydroxyzine Pamoate Generic 26 $193
Clindamycin Hcl Generic 69 $191
Meloxicam Generic 32 $162

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$239,935

Of which drugs: $3,896

Medicare patients

338

Average age 75

Services billed

2,857

207 women, 131 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 58%
Depression 22%
Ischemic heart disease 17%
Osteoporosis 17%
Diabetes 16%
Atrial fibrillation 14%
Chronic kidney disease 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 14 1,320 $135

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

72 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adult Reconstructive Orthopaedic Surgery in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record